Comparative Pharmacology
Head-to-head clinical analysis: METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE versus TRANDATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE versus TRANDATE.
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE vs TRANDATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metoprolol is a cardioselective beta-1 adrenergic receptor antagonist that reduces heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water, thereby reducing plasma volume and blood pressure.
Competitive antagonist at beta-1 and beta-2 adrenergic receptors; also blocks alpha-1 adrenergic receptors, causing vasodilation.
Oral: 50-100 mg metoprolol tartrate/12.5-25 mg hydrochlorothiazide once or twice daily; maximum 200 mg metoprolol/50 mg hydrochlorothiazide per day.
Initial: 100 mg orally twice daily, titrate to 200-400 mg twice daily; maximum 2400 mg/day. Alternatively, 20 mg IV bolus over 2 minutes, then 40-80 mg IV at 10-minute intervals as needed; IV infusion: 2 mg/min, titrate to response.
None Documented
None Documented
Metoprolol: 3–7 h (terminal), clinical context: may require twice-daily dosing; prolonged in hepatic impairment. Hydrochlorothiazide: 6–15 h (terminal), clinical context: supports once-daily dosing; prolonged in renal impairment.
Terminal elimination half-life is approximately 6-8 hours in healthy individuals, but may be prolonged in patients with hepatic impairment or severe renal dysfunction (up to 12-16 hours).
Metoprolol: <5% renal (unchanged), >95% hepatic metabolism, metabolites excreted renally. Hydrochlorothiazide: >95% renal (unchanged).
Labetalol is extensively metabolized in the liver via glucuronidation; less than 5% of the dose is excreted unchanged in urine. Approximately 55-60% of metabolites are excreted renally, and about 30% in feces via biliary secretion.
Category C
Category C
Beta-Blocker
Beta-Blocker